C. Vassallo, B. Canali, F. Fiorentino, P. Morelli, S. Ripoli, and L. Fioravanti, “Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy”, AboutOpen, vol. 10, no. 1, pp. 103–109, Oct. 2023.